Drug intelligence / Profile preview

polyG3

Development stage
Preclinical
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Subcutaneous, Intravenous
01

Overview

polyG3 is a synthetic, guanosine-rich oligonucleotide that functions as a selective agonist for Toll-like receptor 8 (TLR8). It is primarily utilized in immunological research to study the activation of the TLR8 pathway and its downstream effects on innate and adaptive immune responses. In oncology research, particularly concerning multiple myeloma, polyG3 is used to investigate the modulation of myeloid-derived suppressor cells (MDSCs). By activating TLR8, polyG3 can attenuate the MDSC-mediated induction of T-cell senescence, suggesting a potential mechanism for overcoming immune evasion in the tumor microenvironment. The agent has been shown to reduce SA-β-gal-positive staining in T cells when co-cultured with treated monocytic MDSCs (M-MDSCs), thereby potentially reversing the immunosuppressive effects that facilitate tumor growth and stemness maintenance.

Other names
poly-G3poly-G-3poly-G 3TLR8 agonist polyG3TLR-8 agonist polyG3TLR 8 agonist polyG3
02

Targets

TLR8 (Toll-like receptor 8)

Beyond the preview

Go deeper on polyG3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on polyG3.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call